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ABSTRACT: The present paper describes simple, accurate, rapid, precise and sensitive UV spectrophotometric absorption 
correction method for the simultaneous determination of amlodipine and aliskiren in combined tablet dosage form. methanol was 
used as solvent. The wavelengths selected for the analysis using absorption correction method were 354.5  nm and 256.0 nm for 
estimation of amlodipine and aliskiren respectively. Beer’s law obeyed in the concentration range of 10-60 µg/mL and 20-120 
µg/mL for amlodipine and aliskiren, respectively. The mean percentage drug content for amlodipine and aliskiren were found to 
be 99.9. ± 1.38 and 99.87 ± 1.25 respectively and the % RSD value was found to be less than 2 which shows the precision 
of method. The high recovery and low coefficients of variation conforms the suitability for the routine quality control analysis of 
amlodipine and aliskiren in pure and pharmaceutical dosage forms.  
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INTRODUCTION 
Aliskiren(2S,4S,5S,7S)-5-amino-N-(2-carbamoyl-2,2-dimethylethyl)-4-hydroxy-7-{[4-methoxy-3-(3 methoxypropoxy) 
phenyl]methyl}-8-methyl-2-(propan-2-yl) nonanamide (Fig.1) is rennin inhibitor approved for clinical use, exhibits a novel and 
advantageous pharmacokinetic and pharmacodynamic profile for the long-term treatment of hypertension. Aliskiren blocks the 
renin system at its rate-limiting step by directly inhibiting the catalytic activity of renin, thereby reducing generation of 
angiotensin I and angiotens in II [1]. Literature survey revealed HPLC[2], RP-HPLC[3-5], simultaneous UVspectrophotometric [6] 
and  spectroflurimetric[7] methods are reported for the estimation of aliskiren hemifumarate alone or in combination with other 
anti-hypertensive agents. Amlodipine ((RS)-3-ethyl 5-methyl 2-[(2- aminoethoxy) methyl]-4-(2-chlorophenyl)-6- methyl- 1, 4-
dihydropyridine-3,5-dicarboxylate )[8] is long acting calcium channel blockers used as an antihypertensive and in the treatment of 
angina. It acts by relaxing the smooth muscle in the atrial wall, decreasing total peripheral resistance and hence reducing blood 
pressure, in angina it increases blood flow to the heart muscle. Various analytical methods have been reported for the assay of 
Amlodipine in pure form as well as in pharmaceutical formulation. They include HPLC [9, 10], HPTLC [11], RP-HPLC [12, 13], Gas 
chromatography [14], mass-spectrometry [15], and flourimetry[16]. Aliskiren and Amlodipine combination is not official in any 
pharmacopeias so any official analytical method is not available for estimation of these two drugs. One spectroscopy method is 
available for estimation of Aliskiren and Amlodipine in tablet dosage form [17]. But no any absorbance correction method is 
available for determination of Aliskiren and Amlodipine in combine dosage forms. So aim of the present study was to develop 
accurate, precise and selective absorbance correction method assay procedure for the analysis of Aliskiren and Amlodipine in 
combined dosage forms. 
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 EXPERIMENTAL 
 Apparatus 
 A double beam UV-visible Spectrophotometer (Shimadzu, UV-1700, Japan), attached to a computer software UV probe 2.0, 
with a spectral width of 2 nm, wavelength accuracy of 0.5 nm and pair of 1 cm matched quartz cells, Sartorius CP224S analytical 
balance (shimadzu, Japan),Ultra sonic cleaner (Life care eq. PVT. LTD, Mumbai, India), Corning volumetric flasks, pipettes of 
borosilicate glass were used in the study. 
 Reagents and Materials 
Pharmaceutical grade of Aliskiren (ALK) as a gift samples from Novartis India limited, India and Amlodipine besylate were 
kindly supplied as a gift samples from Torrent research centre, Gujarat (India),The pharmaceutical formulation (Tekamlo™) 
containing 150 mg ALK and 5 mg AML was procured from the local pharmacy, AR grade Methanol (S.D. Fine Chemical Ltd., 
Mumbai, India), Whatman filter paper no. 41 (Whatman International Ltd., England). Preparation of ALK and AML Standard 
Solutions 
A mixed stock solution of ALK (2000 µg/Ml) and AML (1000 µg/Ml was prepared by accurately weighing ALK (200 mg) and 
Amlodipine besylate (138 mg) which is equivalent to AML (100 mg), dissolving in methanol and diluted to 100 Ml with 
methanol in the same volumametric flask  
 Preparation of Sample Solutions 
Twenty tablets were weighed and powdered. The quantity of the powder equivalent to 150 mg of ALK and 5 mg of AML was 
transferred to a 100 Ml volumetric flask. The content was mixed with methanol (60 Ml), sonicated for 20 min. to dissolve the 
drug as completely as possible. The solution was then filtered through a Whatman filter paper no. 41. The volume was adjusted 
up to the mark with methanol. An aliquot of this solution (0.6 Ml) was transferred in to a 10 Ml volumetric flask and Addition of 
2 Ml AML standard solution (100ȝg/Ml) to the same volumetric flask.  Methanol was transferred to this volumetric flask and 
Volume was made up to the mark to give a solution containing 90 ȝg/Ml ALK and 23ȝg/Ml AML. This solution was used for the 
estimation of ALK and AML.  
Determination of the analytical wavelengths 
Absorbance spectrum of pure AML was scanned in the spectrum basic mode. Using the cursor function, the absorbance 
corresponding to 354.5 nm (wavelength Ȝ1 for AML) was noted from spectrum. Then the cursor function was moved along with 
peak curve until the absorbance equal to that of absorbance at 354.5 nm was found. The wavelength obtain corresponding to this 
absorbance value was 256 nm (wavelength Ȝ2). The absorbance of various dilutions of AML in methanol was measured at 354.5 
nm. Absorbance spectrum of pure ALK was also scanned in the spectrum basic mode. ALK showed some absorbance value at 
256.0 nm (Ȝ2) while it dose not show any absorbance value at 354.5 nm. The absorbance value at 354.5 nm is due to AML only 
in the combined mixture of both drugs. Wavelength Ȝ1 (354.5 nm) was selected for the measurement of AML. 
METHOD VALIDATION: 
Calibration curve (Linearity) 
Calibration curves were plotted over a concentration range of 20-120 µg/Ml for ALK and 10-60 µg/Ml for AML. Accurately 
measured mixed standard working solutions of ALK and AML (0.1, 0.2, 0.3, 0.4, 0.5, 0.6, and 0.7 Ml) were transferred to a 
series of 10 Ml of volumetric flasks and diluted to the mark with methanol and absorbance’s were measured at 354.5 nm and 256 
nm for both the drugs. The calibration curves were constructed by plotting absorbance at 354.5 nm versus concentrations for 
AML and absorbance difference (A256 - A354.5) vs concentration for ALK.   
Accuracy (% Recovery) 
The accuracy of the method was determined by calculating recovery of ALK and AML by the standard addition method. 
Standard solutions of ALK (20, 40, 60 µg/Ml) for and AML (10, 20, 30 µg/Ml) were added to prequantified sample solutions of 
ALK (40 µg/Ml) and AML (20 µg/Ml) tablet dosage form. The amounts of ALK and AML were estimated by applying obtained 
values to the regression equation of the calibration curve. 
Method Precision (% Repeatability) 
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The precision of the instruments was checked by repeated scanning and measurement of absorbance of solution of (n = 6) of 
ALK and AML (40 µg/Ml) without changing the parameter. 
Intermediate Precision (Reproducibility) 
The intraday and interday precisions of the proposed method was determined by estimating the corresponding responses 3 times 
on the same day and on 3 different days over a period of one week for 3 different concentrations of standard solutions of ALK 
(40, 80, and 120 µg/Ml) and AML (20, 40, and 60 µg/Ml). The results were reported in terms of relative standard deviation (% 
RSD). 
Limit of Detection and Limit of Quantification   
LOD and LOQ of the drug were calculated using the following equations designated by International Conference on 
Harmonization (ICH) guideline: 
 LOD = 3.3 ×  /S 
 LOQ = 10 ×  ҡS 
Where  ҏ= the standard deviation of the response  
S = Slope of calibration curve. 
 
ANALYSIS OF ALK AND AML IN COMBINED DOSAGE FORM:- 
The response of formulations was measured at 354.5nm and 256 nm for AML and ALK, respectively by proposed method as 
described above. The amounts of ALK and AML present in sample solution were determined by fitting the responses into the 
regression equation of calibration curve of the proposed method. 
RESULTS AND DISCUSSION 
Method development 
The utility of dual wavelength data processing program is its ability to calculate unknown concentration of component of interest 
in a mixture containing an interfering component. For elimination of the effects of an interfering component, two specific 
wavelengths are chosen. First wavelength Ȝ1 at which minimum absorbance of AML was observed and there was no interference 
of ALK at this wavelength (354.5nm). Second wavelength Ȝ2 was the wavelengths at which the absorbance of AML was same as 
at Ȝ1,    and also ALK was also give some absorbance at this wavelength (256.0 nm). In this proposed method the absorbance of 
ALK  alone  in  a  mixture  of  ALK  and  AML  was  determined  using  dual  wavelength  data  processing  program.  To  remove  the  
interference of AML to the absorbance at 256.0 nm (Ȝ2), the wavelength of minimum absorbance for AML, another wavelength 
354.5nm (Ȝ1) was found out at which the absorbance of ALK was zero. This was confirmed by measuring the absorbance of 
various dilution of AML in methanol at 256.0 nm and 354.5nm. The absorbance at these two wavelengths was found to be equal. 
These two selected wavelengths were employed to determine the concentration of ALK from the mixture of ALK and AML 
(Figure 1). The difference in absorbance at these two wavelengths (A256.0 – A354.5) cancels out the contribution of absorbance of 
AML in mixture. 
Validation of proposed method [18] 
The proposed method has been validated for the simultaneous determination of ALK and AML in tablet dosage form using 
following parameters. 
 Linearity  
Linear correlation was obtained between absorbance Vs concentrations of ALK in concentration range 20-120 µg/Ml and AML 
in concentration range of 10-60 µg/Ml for proposed method. Regression parameters are mentioned in table 1  
Accuracy  The recovery experiment was performed by the standard addition method. The mean recoveries were 99.87 ± 1.25 and 
99.9. ± 1.38 % for ALK and AML, respectively (Table 1). The low value of standard deviation indicates that the proposed 
method is accurate. Results of recovery studies are shown in Table 2 
Method precision (% Repeatability)  
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 The % RSD values for ALK and AML were found to be 1.94 and 1.61 for Absorbance correction method (Table 1 & Table 3). 
The low values of RSD indicate the proposed methods are repeatable.  
Intermediate precision  
 The low RSD values of interday (1.45-2.01% and0.73-1.84%) and intraday (1.07-1.96 % and 0.47-1.72 %) variations for ALK 
and AML, respectively, reveal that the proposed method is precise (Table 1). 
 
 
TABLE 1 Regression analysis data and summary of validation parameters for the proposed method. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 2 Recovery Data for the Proposed Method 
 
Drug Level Amount of 
sample taken 
(µg/mL) 
Amount of 
standard   spiked 
(%) 
Mean 
% Recovery ± SD* 
ALK I 40 50 % 
 
99.11 ± 0.75 
II 40 100 % 
 
100.2 ± 1.39 
III 40 150 % 100.3 ± 1.6 
PARAMETERS ABSORBANCE 
CORRECTION METHOD 
ALK AML 
Concentration range 
(µg/mL) 
20-120  10-60  
Slope 0.001 0.012 
Intercept 0.020 0.076 
Correlation coefficient 0.999 0.997 
LOD (µg/mL)                      3.68 0.74 
LOQ (µg/mL) 11.16 2.24  
% recovery (Accuracy, 
n = 6) 
99.87 ± 1.25 99.9. ± 1.38 
Repeatability (% RSD, 
n = 6) 
1.94 1.61 
Interday (n = 6) 1.45-2.01 0.73-1.84 
Intraday (n = 6) 1.07-1.96 0.47-1.72 
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AML I 20 50 % 
 
99.12 ± 0.91 
II 20 100 % 
 
100.8 ± 1.79 
III 20 150 %     99.77 ± 1.45 
   * Mean % Recovery ± SD of six observations. 
 
 
 
TABLE 3 Precision Data for Aliskiren and Amlodipine  
ALK and AML 
(40 µg/ml) 
Absorbance diffrence Absorbance at 354.5nm 
1 0.043 0.399 
2 0.042 0.394 
3 0.041 0.391 
4 0.041 0.389 
5 0.042 0.385 
6 0.043 0.402 
Mean 0.042 0.393 
S.D. 0.00081 0.00634 
%CV 1.94 1.61 
 
TABLE 4 Analysis of Marketed Formulation of Aliskiren and Amlodipine by Proposed Method (n = 6) 
Sample No. 
Label Claim Amount Found % Label Claim 
ALK 
(mg/tab) 
AML 
(mg/tab) 
ALK 
(mg/tab) 
AML 
(mg/tab) 
ALK 
(mg/tab) 
AML 
(mg/tab) 
1 150 5 151.7 5.03 101.13 100.7 
2 150 5 151.6 4.96 101.09 99.2 
3 150 5 149.7 5.08 99.8 101.6 
4 150 5 149.1 5.07 99.4 101.4 
5 150 5 153.0 4.92 102 98.4 
6 150 5 149.1 5.02 99.4 100.4 
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Mean 150.70 5.01 100.47 100.28 
S.D. 1.62 0.06 1.08 1.23 
 
LOD and LOQ  
LOD for ALK and AML were found to be 3.68 µg/Ml and 0.74 µg/Ml, respectively. LOQ for ALK and AML were found to be 
11.16 µg/Ml and 2.24 µg/Ml, respectively (Table 1). These data show that method is sensitive for the determination of ALK and 
AML. 
 
 
Assay of the pharmaceutical formulation  
The proposed validated method was successfully applied to determine ALK and AML in their combined dosage form. The 
spectrum of sample is shown in Fig. 2.  The results obtained for ALK and AML were comparable with the corresponding labeled 
amounts (Table 4).  
 
 
FIGURE: 1 Overlain absorption spectra of standard solution of Aliskiren (60 ug /ml) and Amlodipine (30ug/ml) in 
methanol 
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FIGURE 2 Absorption Spectra of sample solution of Aliskiren and Amlodipine in methanol 
 
CONCLUSION: 
In this proposed method the linearity is observed in the concentration range of 20 – 120 µg/Ml with co-efficient of correlation, 
(r2) = 0.999 and 10 – 60 µg/Ml with co-efficient of correlation (r2) = 0.997 for ALK and AML, respectively. 
The result of the analysis of pharmaceutical formulation by the proposed method is highly reproducible and reliable and it is in 
good agreement with the label claim of the drug. The method can be used for the routine analysis of the ALK and AML in 
combined dosage form without any interference of the excipients.   
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